Zobrazeno 1 - 10
of 1 077
pro vyhledávání: '"B. Nixon"'
Autor:
Julia C.F. Quintanilha, Alexander B. Sibley, Yingmiao Liu, Donna Niedzwiecki, Susan Halabi, Layne Rogers, Bert O’Neil, Hedy Kindler, William Kelly, Alan Venook, Howard L. McLeod, Mark J. Ratain, Andrew B. Nixon, Federico Innocenti, Kouros Owzar
Publikováno v:
BMC Genomics, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Herein, we report results from a genome-wide study conducted to identify protein quantitative trait loci (pQTL) for circulating angiogenic and inflammatory protein markers in patients with metastatic colorectal cancer (mCRC). The
Externí odkaz:
https://doaj.org/article/363d6f8837684c528d797df314a685cf
Autor:
Alex S. Choi, Laura M. Jenkins-Lane, Wade Barton, Asha Kumari, Carly Lancaster, Calen Raulerson, Hao Ji, Diego Altomare, Mark D. Starr, Regina Whitaker, Rebecca Phaeton, Rebecca Arend, Michael Shtutman, Andrew B. Nixon, Nadine Hempel, Nam Y. Lee, Karthikeyan Mythreye
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-21 (2024)
Abstract In pathologies including cancer, aberrant Transforming Growth Factor-β (TGF-β) signaling exerts profound tumor intrinsic and extrinsic consequences. Intense clinical endeavors are underway to target this pathway. Central to the success of
Externí odkaz:
https://doaj.org/article/ed54a9e793e64950bc11bf6731d8ff90
Autor:
Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary, Herbert Newton, Ahmad Ozair, Atulya A. Khosla, Andrew B. Nixon, Bonne J. Adams, Ben K. Seon, David M. Peereboom, Charles P. Theuer
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-7 (2023)
Abstract Background Glioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and bevacizumab. TRC105 (carotuximab), a chimeric anti-endoglin (CD105) antibody, inhibits angiogenesis an
Externí odkaz:
https://doaj.org/article/489e8a21a0c84f6195ce4cbc9fe62530
Autor:
Ben Horst, Shrikant Pradhan, Roohi Chaudhary, Eduardo Listik, Liz Quintero-Macias, Alex Seok Choi, Michael Southard, Yingmiao Liu, Regina Whitaker, Nadine Hempel, Andrew Berchuck, Andrew B. Nixon, Nam Y. Lee, Yoav I. Henis, Karthikeyan Mythreye
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-20 (2022)
Hypoxia increases levels of the heteromeric TGFβ ligand inhibin in ovarian cancer and inhibin promotes tumor growth, endothelial cell invasion and permeability.
Externí odkaz:
https://doaj.org/article/8aa175fae86f4fefa2a262cdf7ac53bd
Autor:
Sarah E. Wetzel-Strong, Shantel Weinsheimer, Jeffrey Nelson, Ludmila Pawlikowska, Dewi Clark, Mark D. Starr, Yingmiao Liu, Helen Kim, Marie E. Faughnan, Andrew B. Nixon, Douglas A. Marchuk
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-10 (2021)
Abstract Background Vascular malformations in the central nervous system are difficult to monitor and treat due to their inaccessible location. Angiogenic and inflammatory proteins are secreted into the bloodstream and may serve as useful biomarkers
Externí odkaz:
https://doaj.org/article/d85e9edd018b48bd8a324e4faa6a3311
Autor:
Zainab Shonibare, Mehri Monavarian, Kathleen O’Connell, Diego Altomare, Abigail Shelton, Shubham Mehta, Renata Jaskula-Sztul, Rebecca Phaeton, Mark D. Starr, Regina Whitaker, Andrew Berchuck, Andrew B. Nixon, Rebecca C. Arend, Nam Y. Lee, C. Ryan Miller, Nadine Hempel, Karthikeyan Mythreye
Publikováno v:
Cell Reports, Vol 40, Iss 4, Pp 111066- (2022)
Summary: Growth factors in tumor environments are regulators of cell survival and metastasis. Here, we reveal the dichotomy between TGF-β superfamily growth factors BMP and TGF-β/activin and their downstream SMAD effectors. Gene expression profilin
Externí odkaz:
https://doaj.org/article/20e1a0843b1f45028091a733956f68ac
Autor:
Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100337- (2022)
Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. Methods: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatmen
Externí odkaz:
https://doaj.org/article/4e8e10cbb46b4c6b9961babf7e012e44
Autor:
Sharareh Siamakpour-Reihani, Felicia Cao, Jing Lyu, Yi Ren, Andrew B. Nixon, Jichun Xie, Amy T. Bush, Mark D. Starr, James R. Bain, Michael J. Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L. Huebner, Nelson J. Chao, Anthony D. Sung
Publikováno v:
PLoS ONE, Vol 17, Iss 6 (2022)
Although hematopoietic stem cell transplantation (HCT) is the only curative treatment for acute myeloid leukemia (AML), it is associated with significant treatment related morbidity and mortality. There is great need for predictive biomarkers associa
Externí odkaz:
https://doaj.org/article/b4b09d353c214ef2b6362d7af17d6400
Autor:
John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A. Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended ph
Externí odkaz:
https://doaj.org/article/cee4dcf4fc8d4276878e7ac77b99ef23
Autor:
Andrew B. Nixon, Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang, Catherine Fleener
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract The immunologic landscape of the host and tumor play key roles in determining how patients will benefit from immunotherapy, and a better understanding of these factors could help inform how well a tumor responds to treatment. Recent advances
Externí odkaz:
https://doaj.org/article/ab04ae0cd4854d0181710f053db51ee0